An Observational Study to Evaluate the Clinical Effectiveness, Quality of Life, Safety and Tolerability of Tocilizumab (TCZ) in Patients With Rheumatoid Arthritis (RA) in Daily Clinical Practice

Sponsor
Hoffmann-La Roche
Study ID
NCT02552940
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Tocilizumab — DRUG
    Participants with RA receive TCZ SC, as per routine clinical practice and are followed for approximately 6 months.

Study Details

This observational trial will evaluate the effectiveness, the consistency of evaluation scores, quality of life, safety and tolerability of TCZ administered subcutaneously (SC) in participants with RA in daily clinical practice.

Key Dates

Start date
Oct 31, 2015
Status verified
May 2018
Primary completion
Oct 23, 2017
Completion
Oct 23, 2017

Study Design

Enrollment
140 participants (actual)

Arms

  • Arm: Rheumatoid Arthritis participants treated with Tocilizumab SC
    Participants with RA receive TCZ SC, as per routine clinical practice and are followed for approximately 6 months.

Primary Outcome Measure

Correlation coefficient between DAS28 - erythrocyte sedimentation rate (DAS28-ESR) and Clinical Disease Activity Index (CDAl) [ Time Frame: Up to Week 24 ]

Related Studies